Literature DB >> 1655897

Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells.

A Granelli-Piperno1, P Nolan.   

Abstract

Prior studies have identified several elements that contribute to the activity of the IL-2 promoter in the stimulated T cell line, Jurkat. The sites and their corresponding nuclear binding factors include: NF-kappa B, AP-1, AP-3, OCT-1, and NF-AT. The latter "nuclear factor for activated T cells" likely contributes to the tissue specificity of IL-2 gene expression. Using electrophoretic mobility shift assays, we have studied these transcription factors in primary T cells from human blood to verify their presence in a physiologic setting and to identify the signals that stimulate factor activity. All factors are induced in the nuclei of T cells upon activation with mitogens but not with exogenous IL-2 growth factor. However, the signaling requirements and sensitivity to protein synthesis inhibitors differ considerably. Only the activities for NF-AT and AP-1 sites require two signals for optimal induction, i.e., PMA plus either lectin or antibody to the CD3 or CD28 surface molecules. Other factors are induced by lectin, antibody, and/or PMA alone. After appropriate stimulation, both NF-AT and AP-1 are peculiarly sensitive to the protein synthesis inhibitor anisomycin. Our data correlate the activity of NF-AT and AP-1 in gel shift assays with the two signals requirements for IL-2 gene expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells.

Authors:  T Labuda; E Parra; G Hedlund; T Kalland; M Dohlsten
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 2.  Diverse roles of integrins in human T lymphocyte biology.

Authors:  Yuko J Miyamoto; Bernard F Andruss; Jason S Mitchell; Matthew J Billard; Bradley W McIntyre
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

4.  Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells.

Authors:  A Granelli-Piperno; P McHugh
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes.

Authors:  G Baier-Bitterlich; F Uberall; B Bauer; F Fresser; H Wachter; H Grunicke; G Utermann; A Altman; G Baier
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

6.  Oct-1 [corrected] and Oct-2 DNA-binding site specificity is regulated in vitro by different kinases.

Authors:  S J Grenfell; D S Latchman; N S Thomas
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

7.  Oxidative stress suppresses transcription factor activities in stimulated lymphocytes.

Authors:  E Flescher; H Tripoli; K Salnikow; F J Burns
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

8.  Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells.

Authors:  R G Bryan; Y Li; J H Lai; M Van; N R Rice; R R Rich; T H Tan
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia.

Authors:  A Granelli-Piperno; M Pope; K Inaba; R M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Defective functional response to membrane stimuli in lymphocytes from patients with benign prostatic hyperplasia.

Authors:  M Pérez-Blas; B Martínez-Martín; J Carballido; J Hontoria; L I Salazar; C Olivier; M Alvarez-Mon
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.